BioCentury | Jun 23, 2020
Distillery Therapeutics

An HIV vaccine stimulating T cell and antibody responses

...vector, a vaccinia virus vector and an adenovirus serotype 5 vector that each express the HIV gag polyprotein...
...in Phase I testing to prevent HIV. TARGET/MARKER/PATHWAY: HIV env; toll-like receptor 7 (TLR7); TLR8; HIV gag polyprotein...
...Pulendran, Stanford University School of Medicine, Stanford, Calif. e-mail: bpulend@stanford.edu Claire Quang 3M-052, MEDI9197 Stanford University Emory University University of Minnesota HIV gag polyprotein HIV...
BioCentury | Aug 29, 2019
Distillery Therapeutics

Cytomegalovirus vectors could form the backbone of an HIV vaccine

...an rhesus CMV (RhCMV) vector attenuated to reduce spread and expressing SIV proteins corresponding to HIV gag polyprotein...
...collaboration with Vir Biotechnology Inc. (see "Cytomegalovirus Vectors for a Prophylactic HIV Vaccine" ). TARGET/MARKER/PATHWAY: HIV gag polyprotein...
BioCentury | Jul 18, 2019
Distillery Therapeutics

CRISPR plus antiretroviral therapy could remove HIV virus from cells

...in a mouse model of the disease. After combining long-acting antiretroviral therapy with CRISPR-Cas9 targeting HIV gag polyprotein...
...by year end; the company plans to submit an IND to FDA in 1H20. TARGET/MARKER/PATHWAY: HIV gag polyprotein...
BioCentury | Aug 23, 2018
Distillery Therapeutics

Infectious

...HIV-1 infection. Sanofi has Alvac-HIV (vCP205), a live recombinant canarypox vector vaccine expressing HIV gp120, HIV gag polyprotein...
BioCentury | Jul 25, 2017
Distillery Therapeutics

Infectious disease

...with a primary vaccine consisting of a canarypox viral vector encoding HIV-1 subtype E gp120, HIV gag polyprotein...
...conformationally constrained gp120 immunogen, in Phase I testing to prevent HIV infection. TARGET/MARKER/PATHWAY: HIV gp120; HIV gag polyprotein...
...email: todd.bradley@duke.edu CONTACT: Barton F. Haynes, same affiliation as above email: barton.haynes@duke.edu Hongjiang Li Duke University Medical Center HIV gag polyprotein HIV...
BioCentury | May 26, 2017
Clinical News

Inovio reports Phase I data for HIV vaccine Pennvax-GP

...Washington, D.C. Inovio Pharmaceuticals Inc. (NASDAQ:INO), Plymouth Meeting, Pa. Product: Pennvax-GP Business: Infectious Molecular target: HIV gag polyprotein...
...cell response rate and magnitude Status: Phase I data Milestone: NA Jaime De Leon INO-9012 Pennvax-GP Inovio Pharmaceuticals Inc. HIV env HIV gag polyprotein HIV...
BioCentury | May 24, 2017
Clinical News

Inovio gains on HIV vaccine data

...Tuesday at the 2017 HVTN Spring Full Group Meeting in Washington, D.C. Becky Simon Pennvax-GP Inovio Pharmaceuticals Inc. HIV env HIV gag polyprotein HIV...
BioCentury | Jan 18, 2017
Distillery Therapeutics

Infectious disease

...an HIV-1-infected human cell line expressing Cas9, lentiviral vector-encoded guide RNAs targeting the combination of HIV gag polyprotein...
...HIV infection. TARGET/MARKER/PATHWAY: CRISPR-associated protein 9 (Cas9); HIV tat protein (HIV tat); HIV reverse transcriptase; HIV gag polyprotein...
...Atze T. Das, same affiliation as above email: a.t.das@amc.uva.nl Hongjiang Li University of Amsterdam CRISPR-associated protein 9 (Cas9) HIV env HIV gag polyprotein HIV...
BioCentury | Sep 21, 2015
Clinical News

Pennvax-GP: Phase I started

...the trial. Inovio Pharmaceuticals Inc. (NASDAQ:INO), Blue Bell, Pa. Product: Pennvax-GP Business: Infectious Molecular target: HIV gag polyprotein...
BioCentury | Jul 16, 2015
Distillery Therapeutics

Therapeutics: HIV env; HIV gag polyprotein; HIV pol; HIV gp140

...model of chimeric SIV/HIV (SHIV) infection, immunization with an adenoviral vaccine expressing HIV env , HIV gag polyprotein...
...steps include clinical testing of the adenoviral vaccine and HIV gp140 combination. TARGET/MARKER/PATHWAY: HIV env; HIV gag polyprotein...
Items per page:
1 - 10 of 27